Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.

BMC infectious diseases - 18 Sept 2014

Rasi Manuela, Künzler-Heule Patrizia, Schmid Patrick, Semela David, Bruggmann Philip, Fehr Jan, Saxer Susi, Nicca Dunja

Abstract excerpt

BACKGROUND: Hepatitis C virus (HCV) infections are a severe burden on public health worldwide, causing mortality rates triple that of the general population. Since 2011, for both therapy-naive and therapy-experienced genotype 1 patients, the first generation of direct acting antivirals (DAAs), i.e., the protease-inhibitors (PI) telaprevir and boceprevir have been added to existing dual therapies. The therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Evaluation Studies as Topic

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 25231646
DOI: 10.1186/1471-2334-14-507
PMCID: PMC4174651

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

"Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.PMID 25231646Read ↗

Into the light: strategies for battling hepatitis C.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].Semantic proximity Read ↗

Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.Semantic proximity Read ↗

A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapiesSemantic proximity Read ↗

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.Semantic proximity Read ↗

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.Semantic proximity Read ↗

Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.Semantic proximity Read ↗

Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysisSemantic proximity Read ↗

The role of triple therapy in HCV genotype 1-experienced patients.Semantic proximity Read ↗

First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.Semantic proximity Read ↗

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.